{
  "report_rows": [
    {
      "kpi": "Q2 2026 non-GAAP diluted EPS",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.28 vs. cons $1.27",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 total net sales",
      "prediction": "IN-LINE",
      "answer": "pred ~$3.39B vs. cons $3.37B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 2026 Adjusted EBITDA",
      "prediction": "BEAT",
      "answer": "pred ~$279M vs. cons $276M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 non-GAAP diluted EPS guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$5.30 midpoint vs. cons $5.31 (FY 2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY 2026 total sales-growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~4.0% midpoint vs. cons 4.1% (FY 2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY 2026 Adjusted EBITDA-growth guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~5.0% vs. cons 5.1% (FY 2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Year-end value-creation savings run-rate commentary",
      "prediction": "UNCHANGED",
      "answer": "guide ~$125M vs. cons ~$125M (exit-rate at FY 2026 year-end)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 1.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.5,
  "day5_path": "FADE",
  "day5_rationale": "A modest Q2 EBITDA beat (~$279M vs. ~$276M) and reaffirmed FY EPS midpoint (~$5.30 vs. ~$5.31 consensus) should support an initial ~+1.5% residual move, but unchanged out-period math leaves limited basis for upward FY 2026/FY 2027 revisions; the residual gain is expected to fade to ~+0.5% by day 5.",
  "day5_confidence": "MEDIUM"
}